Literature DB >> 16052277

Glycoprotein G deletion mutants of equine herpesvirus 1 (EHV1; equine abortion virus) and EHV4 (equine rhinopneumonitis virus).

J Huang1, C A Hartley, N P Ficorilli, B S Crabb, M J Studdert.   

Abstract

Glycoprotein G (gG) deletion mutants of EHV1 and EHV4, designated EHV1DeltagG and EHV4DeltagG, were constructed. The growth characteristics of the EHV1DeltagG mutants were similar to the parent virus. All of the EHV4DeltagG mutants grew more slowly in cell culture and produced plaques of different morphology including smaller size. The yields of both gG deletion mutant viruses in cell culture were similar to the parent viruses. Sequencing of the genes flanking gG, Southern blot, PCR and western blot analyses of the mutant viruses demonstrated that the deletions were as expected, except for EHV4DeltagG mutants, which in addition to deletion of gG contained unexpected deletions in the adjacent down stream gene ORF 71 (glycoprotein 2). Antisera to EHV1DeltagG and EHV4DeltagG neutralised the respective mutant and the parent viruses to the same titre and these antisera could be distinguished from antisera to the wild type viruses in a gG antibody detection ELISA. The mutant viruses may be useful as vaccine candidates and the deletion of gG may act as a marker to distinguish vaccinated from the naturally infected horses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16052277     DOI: 10.1007/s00705-005-0607-9

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  2 in total

1.  In vitro characterization of EHV-4 gG-deleted mutant.

Authors:  Walid Azab; Abuelyazeed El-Sheikh; Azza Abdel-Gawad
Journal:  Virus Genes       Date:  2011-09-29       Impact factor: 2.332

2.  CCL3 and viral chemokine-binding protein gg modulate pulmonary inflammation and virus replication during equine herpesvirus 1 infection.

Authors:  Gerlinde R Van de Walle; Kaori Sakamoto; Nikolaus Osterrieder
Journal:  J Virol       Date:  2007-12-12       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.